Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arovella Therapeutics Limited ( (AU:ALA) ) has provided an update.
Arovella Therapeutics has announced that 936,303 ordinary shares, issued on 4 August 2025 as non-cash consideration for investor relations services, will be released from voluntary escrow on 31 January 2026. The move modestly increases the company’s freely tradable share float, potentially enhancing liquidity in its stock while reflecting the use of equity-based payments to support its investor engagement activities.
The most recent analyst rating on (AU:ALA) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Arovella Therapeutics Limited stock, see the AU:ALA Stock Forecast page.
More about Arovella Therapeutics Limited
Arovella Therapeutics Ltd (ASX: ALA) is an Australian biotechnology company developing an invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers and solid tumours. Its lead product, ALA-101, is an allogeneic CAR19-iNKT cell therapy targeting CD19 and CD1d antigens across multiple cancer types, while the company is also advancing solid tumour programs using CLDN18.2-targeting technology from Sparx Group and IL-12-TM technology.
Average Trading Volume: 1,088,394
Technical Sentiment Signal: Hold
Current Market Cap: A$112.9M
For detailed information about ALA stock, go to TipRanks’ Stock Analysis page.